Marla C Dubinsky, MD
- PROFESSOR | Pediatrics, Gastroenterology
- PROFESSOR | Medicine, Gastroenterology
Specialties:Pediatrics, Pediatric Gastroenterology and Hepatology
Research Topics:Inflammatory Bowel Disease (IBD), Personalized Medicine, Pharmacogenomics
Dr. Dubinsky received her medical degree from Queen’s University, Canada. She completed her Pediatric Residency at Alberta Children’s Hospital, Calgary, Canada and her Clinical Fellowship in Gastroenterology and Nutrition at Sainte-Justine Hospital at the University of Montreal, Canada, She then completed her Research Fellowship in Inflammatory Bowel Disease at Cedars-Sinai Medical Center in Los Angeles where she then served as the Director of the Pediatric Inflammatory Bowel Disease Center before coming to Mount Sinai as the Chief of Pediatric Gastroenterology and Hepatology at the Kravis Children’s Hospital at Mount Sinai. Her primary research focuses on the influence of genetics and immune responses on the variability in clinical presentations, treatment responses and prognosis of early-onset IBD. Her other interests include the impact of IBD on fertility and pregnancy. She has lectured widely both nationally and internationally and has published in 83 peer reviewed journals including Gastroenterology, The Journal of Pediatric Gastroenterology and Nutrition, Inflammatory Bowel Diseases, and the American Journal of Gastroenterology. She also currently sits on the editorial boards of several leading journals, including Gastroenterology, American Journal of Gastroenterology, and Nature Clinical Practice Gastroenterology & Hepatology.
- Crohn's Disease
- Inflammatory Bowel Disease
- Ulcerative Colitis
- Upper GI Endoscopy
MD, Queen's University
Residency, Pediatrics, Alberta Children's Hospital
Fellowship, Pediatric Gastroenterology, CHU Sainte-Justine (St. Justine Hospital)
International Organization for the Study of Inflammatory Bowel Disease
Abe and Claire Levine Chair in Pediatric Inflammatory Bowel Disease
Lectureship Award, University of Calgary
Corrine and Lenny Sands Clinical Investigator Award
Dr. Dubinsky's research interests include:
- Microbiome and genetics
- Pregnancy, preconception, and fertility
- Prognostic models
- Therapeutic drug monitoring
- The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
Small bowel ultrasound (SBUS) is emerging as a well tolerated, non-invasive, radiation free, low cost measure to assess inflammatory bowel disease (IBD), and is being used as first-line imaging in Europe. SBUS findings have been shown to correlate with endoscopic findings, and...
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects with Active Crohn's Disease
Subjects are being asked to take part in this study because they have been diagnosed with Crohn's disease. Crohn's disease (CD) is a chronic (long-lasting) inflammatory (associated with irritation or swelling) disease that may affect any part of the digestive tract. Symp...
Dubinsky M. Have we changed the natural history of pediatric Crohn's disease with biologics? . Dig Dis. 2014; 32(4): 360-3.
Singh N, Rosenthal C, Melmed G, Mirocha J, Farrior S, Callejas S, Tripuraneni B, Rabizadeh S, Dubinsky M. Early Infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. . Inflamm Bowel Dis 2014; 20: 1708-13.
Bradford K, Melmed G, Fleshner P, Silverman N, Dubinsky M. Significant Variation in Recommendation of Care for Women of Reproductive Age with Ulcerative Colitis Postileal Pouch-Anal Anastomosis.. Dig Dis Sci. 2014 Feb 19;.
Vahabnezhad E, Rabizadeh S, Dubinsky M. A 10-Year, Single Tertiary Care Center Experience on the Durability of Infliximab in Pediatric Inflammatory Bowel Disease. . Inflamm Bowel Dis. 2014 Feb 18;.
Dulai P, Thompson K, Blunt H, Dubinsky M, Siegel C. Risks of Serious Infection or Lymphoma with Anti-Tumor Necrosis Factor Therapy for Pediatric Inflammatory Bowel Disease: a Systematic Review.. Clin Gastroenterol Hepatol. 2014 Jan 22;.
Dulai P, Siegel C, Dubinsky M. Balancing and communicating the risks and benefits of biologics in pediatric inflammatory bowel disease.. Inflamm Bowel Dis. 2013; 19: 2927-36.
Dubinsky M, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, Quiros A, Bahar R, Silber G, Farrior S, Stephens M, Teleten N, Panikkath D, Ippoliti A, Vasiliauskas E, Fleshner P, Williams C, Landers C, Rotter J, Targan S, Taylor K, McGovern D. Multi-dimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn’s disease.. Inflamm Bowel Dis 2013; 0: 1-9.
Mahadevan U, Wolf D, Dubinsky M, Cortot A, Lee S, Siegel C, Ullman T, Glover S, Valentine J, Rubin D, Miller J, Abreu M. Placental Transfer of Anti-Tumor Necrosis Factor Agents in Pregnant Patients with Inflammatory Bowel Disease. . Clin Gastroenterol Hepatol. 2013; 11: 286-92.
Siegel C, Siegel L, Hyams J, Kugathasan S, Markowitz J, Rosh J, Leleiko N, Mack D, Crandall W, Evans J, Keljo D, Otley A, Oliva-Hemker M, Farrior S, Langton C, Wrobel I, Wahbeh G, Quiros J, Silber G, Bahar R, Sands B, Dubinsky M. A Real-Time tool to display the predicted disease course and treatment response for children with Crohn's disease. . Inflammatory Bowel Diseases 2011; 17: 30-8.
Dubinsky M, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, Kim C, Glessner J, Targan S, McGovern D, Taylor K, Rotter J. Genome Wide association (GWA) predictors of anti-TNF therapeutic responsiveness in pediatric Inflammatory bowel disease. . Inflammatory Bowel Diseases 2010; 16: 1357-66.